Coronvirus treatment: Plitidepsin, according to the researchers, should be considered for clinical trials based on its in vivo study results. Plitidepsin aka Aplidin is owned by Spanish pharmaceutical company Pharma Mar

The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research

The U.S. drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with a one-dose trial with as many as 60,000 volunteers that began in September

Zydus today said it has filed an Investigational New Drug (IND) application for 'ZYIL1', an oral drug candidate, that has found to be effective in pre-clinic studies to control inflammation in COVID-19 related diseases

\"It (candidate drug PNB-001) has shown remarkable results in lung inflammation and ARDS (Acute Respiratory Distress Syndrome)\", says PN Balaram, CEO of PNB Vesper

WHO's recommendation is based on three new studies, plus four other earlier trials, all involving a drug from the family of corticosteroids

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical

In results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients in what scientists said was a major breakthrough in the coronavirus pandemic

For months before studies like these, learning what helps or harms has been undermined by \"desperation science\" as doctors and patients tried therapies on their own or through a host of studies not strong enough to give clear answers

A week ago, European Medicines Agency gave its go-ahead for remdesivir to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support

While the general opinion of most experts and pharmaceutical companies is that a corona vaccine would be ready by mid-2021, researchers are still hoping for a 2020 breakthrough

\"Remdesavir seems to be useful for those who are coping with the beginning part of the disease and dexamethasone is useful for those who have to deal with the disease in its later phase within the body\"

As per researchers led by a team from the University of Oxford, Dexamethasone has proven to reduced chances of dying from COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%

Coronavirus vaccine update: Moderna has signed a deal with Catalent for large-scale manufacturing of its vaccine candidate. Catalent will provide vial filling and packaging capacity as well as additional workforce required for 24X7 manufacturing operations.

Remdesivir, allowed for emergency use in COVID-19 patients from May 1, is currently given as an injection and can be used only in hospitals

Coronavirus vaccine update: Germany's CureVac AG has received approval from the government to conduct human trials. The coronavirus vaccine candidate would first be tested 168 health people according to the government

On Tuesday, when the British researchers announced their findings, the department of health said the dexamethasone had been approved to treat all hospitalized COVID-19 patients, effectively immediately

According to scientists, the drug has been proven to reduce the risk of death significantly in COVID-19 patients on ventilation by as much as 35 per cent and patients on oxygen by 20 per cent

Scores of domestic flights in and out of Beijing were cancelled on Wednesday as officials ramped up attempts to contain a coronavirus outbreak in the Chinese capital; Dexamethasone, a time-tested steroid used to treat inflammation, can reduce death up to one-third in hospitalised patients with severe respiratory complications of COVID-19, an important large clinical trial by the University of Oxford has said; The US State Department issued a statement on Wednesday regarding the India-China standoff at the Galwan Valley region of Eastern Ladakh. Watch the video for more.Also Read: India-China face-off: Chinese media downplays Galwan Valley border clashes

The Centre had earlier opposed the plea and said these are extraordinary circumstances and the website has been developed for easy accessibility of medicines to COVID-19 patients